Fundraising Fox
/People
Sign in

Brendan Kelly

Investor

Senior Director, Healthcare Venture Investments at Leaps by Bayer

Boston, Massachusetts, United States

Find your path to Brendan

861 people in our graph can introduce you to Brendan.

Each arrow is one introduction. Sign up to fill in the first one.

Ask David Dolby to introduce you to Brendan

You →David · together at Leaps by Bayer (2026) →Brendan

Ask Jamie Chen to introduce you to Brendan

You →Jamie · 9 people · together at Lightstone Ventures →Brendan

Ask Sam Okafor to introduce you to Brendan

You →Sam · together at University of Barcelona →Brendan

Sign up to find every way you can get introduced to Brendan

  • Your email: the people you already email who know Brendan
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Brendan
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Brendan Kelly is Senior Director of Healthcare Venture Investments at Leaps by Bayer. He is a computational medicinal chemist with nine years of research experience across academic and industrial drug discovery teams, including projects with Pfizer and Eli Lilly, and previously conducted postdoctoral research on GPCR signaling in the Stanford University Computer Science Department. He is a founder and board member of A2A Pharmaceuticals, a computational fragment-based drug discovery company focused on oncology and drug-resistant bacterial infections, and has worked as a life sciences consultant and advisor to an early-stage angel investment firm.

Contact· self-published, not guessed

Experience

  1. Leaps by BayerSenior Director, Healthcare Venture Investmentscurrent2026 — presentCambridge, Massachusetts, United States
  2. Lightstone VenturesPrincipal2024 — 2026Boston, Massachusetts, United States
  3. Lightstone VenturesVice President2021 — 2024Boston, Massachusetts, United States
  4. A2A PharmaceuticalsCo-Founder and Strategic Advisor2016 — 2021
  5. A2A PharmaceuticalsHead Of Research And Development2017 — 2018
  6. Q32 Bio Inc.Director, New Product Planning2021Cambridge, Massachusetts, United States
  7. Q32 Bio Inc.Assoc. Director, New Product Planning2020 — 2021Cambridge, Massachusetts, United States
  8. OS FundLife Sciences Venture Advisor2017 — 2021Greater Boston
  9. L.E.K. ConsultingLife Sciences Consultant2020Boston, Massachusetts, United States
  10. L.E.K. ConsultingSenior Life Science Specialist2019 — 2020Greater Boston
  11. L.E.K. ConsultingLife Science Specialist2018 — 2019Boston
  12. Stanford UniversityPostdoctoral Researcher, Computational Drug Discovery2015 — 2017Palo Alto, California
  13. University Health Network, University of TorontoPostdoctoral Fellow2013 — 2015Toronto, Canada
  14. Trinity College Dublin, Department of BiochemistryResearcher2012 — 2013Dublin, Ireland
  15. University of BarcelonaVisiting Researcher2012Greater Barcelona Metropolitan Area
  16. Trinity College DublinLecturer2009 — 2012Dublin, Ireland

Skills & more

Drug Discovery8Molecular Modeling14Molecular Dynamics10Computational Chemistry8Organic Chemistry18Spectroscopy9University Teaching4Medicinal Chemistry18NMR Spectroscopy3Assay Development3Science5Research6
+7 moreChemistryNMROrganic SynthesisScientific WritingMolecular BiologyLife SciencesLinux

Languages English · French · Spanish

From Brendan's professional profile.

Colleagues at Leaps by Bayer

Brendan Kelly, Ph.D.
Principal at Lightstone Ventures
David Dolby
CEO at Dolby Family Ventures
Derek Norman
Vice President at Leaps by Bayer
Naveen Krishnan
Investor at Leaps by Bayer
Paimun Amini
Investor at Leaps by Bayer
Rakhshita Dhar
Investor at Leaps by Bayer

Frequently asked questions

Who is Brendan Kelly?
Brendan Kelly is Senior Director of Healthcare Venture Investments at Leaps by Bayer. He is a computational medicinal chemist with nine years of research experience across academic and industrial drug discovery teams, including projects with Pfizer and Eli Lilly, and previously conducted postdoctoral research on GPCR signaling in the Stanford University Computer Science Department. He is a founder and board member of A2A Pharmaceuticals, a computational fragment-based drug discovery company focused on oncology and drug-resistant bacterial infections, and has worked as a life sciences consultant and advisor to an early-stage angel investment firm.
Where does Brendan Kelly work?
Brendan Kelly is Senior Director, Healthcare Venture Investments at Leaps by Bayer.
Where did Brendan Kelly go to school?
Brendan Kelly studied at Trinity College Dublin (Doctor of Philosophy (Ph.D.), Design, synthesis and evaluation of alpha 2 adrenoceptor antagonists for the treatment of depression); Trinity College Dublin (Bachelor of Science (BSc), Medicinal Chemistry).

Same school

Shared employers